REDWOOD CITY, Calif., November 11, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that a study published in Nature Medicine reinforces the benefits of using the Guardant360® liquid biopsy test to help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC). Led by the National Cancer Center Hospital East (NCCHE) in Japan, the study demonstrates that the Guardant360 test can select patients for HER2-directed ther
REDWOOD CITY, Calif., November 08, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upcoming 2021 Stifel Healthcare Conference.
Earlier today Guardant Health released financial results for the quarter ended September 30, 2021. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO, AmirAli Talasaz, Co-CEO and Mike Bell, Chief Financial Officer. Additional information regarding these risks and uncertainties, appears in the section entitled Forward-Looking Statements in the press release Guardant issued today.